69 related articles for article (PubMed ID: 17195453)
1. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
Oshiro S; Tsugu H; Komatsu F; Ohnishi H; Ueno Y; Sakamoto S; Fukushima T; Soma G
Anticancer Res; 2006; 26(6A):4027-32. PubMed ID: 17195453
[TBL] [Abstract][Full Text] [Related]
2. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Ueno Y; Hayashi S; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(6A):4081-6. PubMed ID: 11131676
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
[TBL] [Abstract][Full Text] [Related]
8. [Intratumoral pharmacokinetics following intraarterial administration of MCNU in patients with malignant gliomas].
Yamasaki T; Nagao S; Kagawa T; Konishi S; Akiyama Y; Fukuda M; Kimura Y; Moritake K
No Shinkei Geka; 1995 Nov; 23(11):963-9. PubMed ID: 7477717
[TBL] [Abstract][Full Text] [Related]
9. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas.
Tsuboi K; Saijo K; Ishikawa E; Tsurushima H; Takano S; Morishita Y; Ohno T
Clin Cancer Res; 2003 Aug; 9(9):3294-302. PubMed ID: 12960115
[TBL] [Abstract][Full Text] [Related]
10. Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients.
McGirt MJ; Goldstein IM; Chaichana KL; Tobias ME; Kothbauer KF; Jallo GI
Neurosurgery; 2008 Jul; 63(1):55-60; discussion 60-1. PubMed ID: 18728568
[TBL] [Abstract][Full Text] [Related]
11. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
12. Clinical results of BNCT for malignant brain tumors in children.
Nakagawa Y; Kageji T; Mizobuchi Y; Kumada H; Nakagawa Y
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S27-30. PubMed ID: 19406652
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor effect of direct intra-tumor administration of OK-432 on malignant glioma: basic and clinical observations].
Fujisawa K; Kanno T; Yokoi K; Onouchi K; Kawase T; Abe M
No Shinkei Geka; 1991 Mar; 19(3):241-6. PubMed ID: 2038413
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
Taguchi T
Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
[TBL] [Abstract][Full Text] [Related]
17. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
[TBL] [Abstract][Full Text] [Related]
19. [Current status of interferon therapy on malignant brain tumor].
Nagai M; Arai T; Kohno S; Iizuka E
Gan No Rinsho; 1983 May; 29(6):608-15. PubMed ID: 6876429
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
